Hypothesis

The BCL-2/Beclin-1 interaction acts as a molecular rheostat that not only modulates basal autophagy but also selectively regulates the cargo loading of the senescence-associated secretory phenotype (SASP). In senescent cells, a balanced BCL-2/Beclin-1 interaction maintains a Goldilocks autophagy level that permits clearance of miMOMP‑damaged mitochondria while favoring the secretion of tissue‑repair SASP factors (e.g., TGF‑β, IGF‑1) and restraining pro‑inflammatory cytokines (e.g., IL‑6, IL‑1α). Disrupting this interaction—either genetically (Beclin‑1 F121A) or pharmacologically—shifts autophagy flux toward excessive, non‑selective autophagosome formation, which redirects cytosolic SASP precursors into degradative pathways and simultaneously unleashes an unchecked NF‑κB‑driven inflammatory secretome. Consequently, senescent cells lose their hostage‑negotiator function and become inflammatory saboteurs that exacerbate tissue damage upon clearance by senolytics.

Mechanistic Rationale

1. Autophagy‑dependent SASP triage – Recent work shows that certain SASP components are secreted via unconventional autophagy‑linked pathways (LC3‑associated secretion) [2]. The BCL-2/Beclin-1 rheostat determines the pool of free Beclin-1 available for these LC3‑associated phagophores, thereby controlling which proteins are packaged for secretion versus degradation.
2. NF‑κB crosstalk – BCL-2 binds Beclin-1 at the ER, limiting its interaction with the autophagy initiation complex. When this bond is weakened, liberated Beclin-1 can scaffold TRAF6‑dependent NF‑κB activation at mitochondria-associated membranes, amplifying transcription of IL‑6 and IL‑1β [3].
3. miMOMP signalling – Senescent cells exhibit minority mitochondrial outer membrane permeabilization (miMOMP) that releases limited cytochrome c, sufficient to activate caspase‑independent pathways that promote SASP but not apoptosis. Adequate autophagy (via BCL-2/Beclin-1) clears the resulting oxidative stress, preserving a reparative secretome. Excessive autophagy degrades antioxidant enzymes (e.g., SOD2), heightening ROS and further driving inflammatory SASP.

Testable Predictions

• Prediction 1: In primary human fibroblasts rendered senescent by irradiation, CRISPR‑engineered Beclin-1 F121A will show a ≥2‑fold increase in LC3‑II flux (measured by bafilomycin A1 blockade) accompanied by a shift in SASP: ELISA will reveal ↓TGF‑β/IGF‑1 (≥30% drop) and ↑IL‑6/IL‑1α (≥2‑fold rise) compared with wild‑type senescent cells.
• Prediction 2: Co‑culture of these Beclin-1 F121A senescent cells with epithelial progenitors will impair colony‑forming efficiency (CFE) by ≥40% relative to wild‑type senescent conditioned medium, an effect rescued by neutralizing IL‑6 antibody.
• Prediction 3: In vivo, Klotho‑deficient mice carrying the Beclin-1 F121A allele treated with a BCL‑2 inhibitor (e.g., ABT‑263) will exhibit exacerbated renal fibrosis (↑collagen I area ≥25%) after senolytic clearance, whereas vehicle‑treated Klotho‑deficient/F121A mice show improved histology.

Experimental Approach

1. Generate isogenic IMR‑90 lines with WT or F121A Beclin-1 via CRISPR‑HDR; confirm senescence (SA‑β‑gal, p16^INK4a^).
2. Measure autophagic flux (LC3‑II/I with/without bafilomycin), mitochondrial ROS (MitoSOX), and miMOMP (Cyto‑c‑GFP release).
3. Profile SASP using multiplex Luminex; focus on TGF‑β, IGF‑1, IL‑6, IL‑1α, MMP‑3.
4. Apply conditioned media to colonic organoid cultures; quantify budding and CFE.
5. In Klotho^−/−;Beclin-1^F121A mice, administer ABT‑263 (50 mg/kg i.p. weekly) for 4 weeks; assess kidney histology (Masson’s trichrome), SASP levels in plasma, and survival.

Falsifiability

If Beclin-1 F121A senescent cells do not show the predicted SASP shift (i.e., TGF‑β/IGF‑1 unchanged or increased, IL‑6/IL‑1α unchanged), or if senolytic treatment in Klotho^−/−;F121A mice improves rather than worsens tissue pathology, the hypothesis would be refuted. Likewise, rescuing the inflammatory SASP with autophagy‑specific inhibitors (e.g., VPS34 antagonist) without affecting BCL‑2/Beclin-1 binding would indicate that the observed effects are autophagy‑dependent, supporting the mechanistic link.

Broader Impact

Reframing senescent cells as dynamic signal tuners governed by the BCL-2/Beclin-1 rheostat suggests that senolytics should be combined with SASP‑modulating adjuvants (e.g., NF‑κB blockers) to avoid trading one pathology for another. It also opens a therapeutic window where fine‑tuning—rather than ablating—the BCL-2/Beclin-1 interaction could preserve the hostage‑negotiator function while limiting deleterious secretory activity.

References

[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC3304572/ [2] https://aacrjournals.org/cancerres/article/66/6/2885/527026/Bcl-2-Inhibition-of-Autophagy-A-New-Route-to [3] https://pmc.ncbi.nlm.nih.gov/articles/PMC3901098/ [4] https://pmc.ncbi.nlm.nih.gov/articles/PMC5992097/ [5] https://pubmed.ncbi.nlm.nih.gov/29849149/